What are the recommended treatments and prophylaxis for acute hepatitis A infection?

Hepatitis A Medication

For acute hepatitis A infection, no specific antiviral treatment exists—management is entirely supportive care, as the infection is self-limited in the vast majority of cases.

Treatment of Acute Hepatitis A

Hepatitis A does not require specific medication for treatment. The infection resolves spontaneously in most patients through supportive measures 1. Key management principles include:

• Supportive care only: Rest, adequate hydration, and nutritional support
• Symptom management: Antiemetics for nausea, analgesics for discomfort (avoid hepatotoxic medications)
• Monitor liver function: Serial transaminases and coagulation studies in symptomatic patients
• No chronic infection occurs: Unlike hepatitis B or C, HAV never causes chronic liver disease 2, 1

Special Circumstances Requiring Consideration

While most cases are self-limited, certain populations may develop severe manifestations 3:

• Fulminant hepatitis (rare): May require liver transplant evaluation
• Prolonged cholestasis: Corticosteroid therapy has shown outcome improvement in limited studies 3
• Vulnerable populations: Pregnant women, immunocompromised individuals, and those with pre-existing liver disease require closer monitoring 3

Important caveat: There is no role for ribavirin, interferon, or other antivirals in hepatitis A—these are only relevant for hepatitis E or other viral hepatitides 3.

Prophylaxis (Prevention)

Postexposure Prophylaxis (PEP)

For healthy individuals aged 12 months to 40 years exposed to hepatitis A, administer hepatitis A vaccine alone within 14 days of exposure 4.

The algorithm for PEP based on age and risk factors 4:

• Age <12 months: Immune globulin (IG) 0.1 mL/kg only
• Age 12 months–40 years (healthy): Hepatitis A vaccine 1 dose
• Age >40 years (healthy): Hepatitis A vaccine 1 dose; provider may add IG 0.1 mL/kg based on risk assessment
• Age ≥12 months (immunocompromised or chronic liver disease): Both vaccine AND IG 0.1 mL/kg simultaneously at different anatomic sites
• Vaccine contraindicated (any age): IG 0.1 mL/kg only

Critical timing: PEP must be administered within 14 days of exposure, ideally as soon as possible. The mean time to vaccination in successful PEP programs is approximately 6.7 days post-exposure 5.

Important pitfall: For those >40 years, vaccine efficacy data is limited. One study found a 12-fold increased risk of secondary infection in those >40 years compared to younger contacts when vaccine alone was used 5. This supports the guideline recommendation to consider adding IG in this age group.

Preexposure Protection (Vaccination)

Routine vaccination is recommended for all children at 12-23 months of age, with catch-up vaccination for those 2-18 years who were not previously vaccinated 2.

Additional populations requiring vaccination 2, 1:

• International travelers to endemic areas
• Persons who use illegal drugs
• Men who have sex with men
• Persons with chronic liver disease or HIV
• Persons experiencing homelessness
• Incarcerated populations
• Anyone requesting protection without specific risk factors

For international travel 4:

• Infants 6-11 months: Give 1 dose before travel (does not count toward routine series)
• Age ≥12 months: Give dose as soon as travel is considered; complete 2-dose series per routine schedule
• Age >40 years or immunocompromised: May add IG 0.1-0.2 mL/kg based on provider risk assessment

The vaccine provides long-term immunity after completing the 2-dose series (second dose at least 6 months after the first) 4, 2.